TY - JOUR
T1 - Glucagon-like peptide-1 receptor expression in normal and neoplastic human pancreatic tissues
AU - Molin, Marco Dal
AU - Kim, Haeryoung
AU - Blackford, Amanda
AU - Sharma, Rajni
AU - Goggins, Michael
N1 - Funding Information:
This work was supported by National Institutes of Health grants (CA62924, R01CA176828), Susan Wojcicki and Dennis Troper, and the Michael Rolfe Foundation.
Publisher Copyright:
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016/3/4
Y1 - 2016/3/4
N2 - Objectives: Studies have proposed pro-oncogenic effects of glucagonlike peptide-1 receptor (GLP-1R) agonists in the pancreas by promoting GLP-1R overactivation in pancreatic cells. However, the expression of GLP-1R in normal and neoplastic pancreatic cells remains poorly defined, and reliablemethods for detecting GLP-1R in tissue specimens are needed. Methods: We used RNA in situ hybridization to quantify glp-1r RNA in surgically resected human pancreatic specimens, including pancreatic ductal adenocarcinoma (PDAC), preinvasive intraepithelial lesions (pancreatic intraepithelial neoplasia), and non-neoplastic ductal, acinar, and endocrine cells. Amixed-effect linear regressionmodelwas used to investigate the relationship between glp-1r signals and all cells, ordered by increasing grade of dysplasia. Results: All cell types had evidence of glp-1r transcripts, with the highest expression in endocrine cells and lowest in ductal cells. The slope of the fitted line was not significantly different from zero (0.07; 95% confidence interval,-0.0094 to 0.244; P = 0.39), suggesting that progression fromnormal cells to PDAC is not associated with a parallel increase in glp-1r RNA. A series of pairwise comparisons between all cell typeswith respect to their glp-1r expression showed no significant difference in glp-1r in cancer, pancreatic intraepithelial neoplasia, and acinar and ductal cells. Conclusions: Our study supports the lack of evidence for GLP-1R overexpression in PDAC.
AB - Objectives: Studies have proposed pro-oncogenic effects of glucagonlike peptide-1 receptor (GLP-1R) agonists in the pancreas by promoting GLP-1R overactivation in pancreatic cells. However, the expression of GLP-1R in normal and neoplastic pancreatic cells remains poorly defined, and reliablemethods for detecting GLP-1R in tissue specimens are needed. Methods: We used RNA in situ hybridization to quantify glp-1r RNA in surgically resected human pancreatic specimens, including pancreatic ductal adenocarcinoma (PDAC), preinvasive intraepithelial lesions (pancreatic intraepithelial neoplasia), and non-neoplastic ductal, acinar, and endocrine cells. Amixed-effect linear regressionmodelwas used to investigate the relationship between glp-1r signals and all cells, ordered by increasing grade of dysplasia. Results: All cell types had evidence of glp-1r transcripts, with the highest expression in endocrine cells and lowest in ductal cells. The slope of the fitted line was not significantly different from zero (0.07; 95% confidence interval,-0.0094 to 0.244; P = 0.39), suggesting that progression fromnormal cells to PDAC is not associated with a parallel increase in glp-1r RNA. A series of pairwise comparisons between all cell typeswith respect to their glp-1r expression showed no significant difference in glp-1r in cancer, pancreatic intraepithelial neoplasia, and acinar and ductal cells. Conclusions: Our study supports the lack of evidence for GLP-1R overexpression in PDAC.
KW - Glucagon-like peptide-1 receptor
KW - Incretins
KW - Pancreatic cancer
KW - Pancreatic intraepithelial neoplasia
UR - http://www.scopus.com/inward/record.url?scp=84945152299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945152299&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000521
DO - 10.1097/MPA.0000000000000521
M3 - Article
C2 - 26495786
AN - SCOPUS:84945152299
SN - 0885-3177
VL - 45
SP - 613
EP - 619
JO - Pancreas
JF - Pancreas
IS - 4
ER -